Sabin Vaccine Institute Concludes 2nd Meeting of the Cancer Vaccine Consortium

NEW CANAAN, CT, November 4, 2003—The Sabin Vaccine Institute, a non-profit research and education organization based in New Canaan, today concluded the second meeting of the Cancer Vaccine Consortium (CVC). The three-day meeting was held in Bethesda, Maryland and drew attendees from the United States, Canada and Europe. The purpose of the CVC is to enhance collaboration among companies undertaking research and development on cancer immunotherapies.

Sabin

Immunotherapies for Cancer Are Focus of Newly Formed Consortium

NEW CANAAN, CT—Treatment options for a variety of cancers are expanding to include an array of exciting new approaches. Along with well-established companies, newer biotechnology and biopharmaceutical firms are looking to break into an emerging market that would provide vaccines for both solid cancers—such as melanoma, prostate, breast, lung, cervical, colon, brain, and ovarian—and blood borne cancers—such as lymphoma, leukemia, and myeloma.

Sabin

Accelerating Cancer Vaccine Development is Rallying Cry at 2003 Colloquium on Cancer Vaccines and Immunotherapy

NEW CANAAN, CT— Cancer vaccines present an elusive goal, yet one that is increasingly within reach for biomedical researchers. Their hope is to offer physicians and cancer patients more and better therapy options than radiation and chemotherapy.

Sabin